ATNM — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-08-07

• Our translational data demonstrated that ATNM-400 is superior to the active ingredients in the many of the most commonly prescribed approved therapies in prostate cancer, NSCLC and breast cancer when tested in a wide variety of preclinical models:

• In addition, we have developed a theranostic strategy utilizing Zr-89 as a companion imaging agent to enable patient selection and tumor visualization. We believe this approach allows for non-invasive assessment of target expression and drug biodistribution prior to therapeutic administration, poten…

• ATNM-400 Is Designed to Address Large, Treatment Resistant Patient Populations Across Prostate, Lung and Breast Cancer - Indications in Which Approved Targeted Therapies Generated More Than $30 Billion in Worldwide Sales in 2025

• We are developing ATNM-400 as a mutation- and pathway-agnostic radiotherapeutic - as a monotherapy or in combination with standard of care - for large, treatment resistant solid tumor populations, with initial focus on prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. These dise…

• Prostate cancer is the most frequently diagnosed cancer in men in the United States. According to the American Cancer Society, approximately 333,830 men in the United States were estimated to be diagnosed with prostate cancer in 2026, representing approximately 30% of all cancer diagnoses in men. Wh…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Our preclinical translational data demonstrated that ATNM-400 is superior to:

• Our preclinical development program has generated encouraging efficacy and mechanism-of-action data across multiple indication-specific animal models:

• ATNM-400 demonstrated specific tumor uptake and decreased tumor cell proliferation across preclinical models representative of clinically relevant mCRPC settings spanning ARPI-resistant disease as well as PSMA-high (C4-2), PSMA-low (22Rv1) and PSMA-negative (DU145) states. The results demonstrate AT…

• ATNM-400 outperformed 177Lu-PSMA-617 (the active ingredient in Pluvicto®) and 225Ac-PSMA-617 in the PSMA-low, ARPI-resistant 22Rv1 prostate cancer model, demonstrating PSMA independent durable activity.

• ATNM-400 Tumor Growth Inhibition vs 177Lu-PSMA-617 and 225Ac-PSMA-617

Text added vs the prior filing · source: 10-Q · 2026-08-07

• ●Limitations under General Instructions I.B.6 of Form S-3 (the “baby shelf limitation) may restrict our ability to raise additional capital;

• Limitations under General Instructions I.B.6 of Form S-3 (the “baby shelf” limitation) may restrict our ability to raise additional capital.

• Although we may continue to offer and sell shares of common stock under our existing at-the-market offering program up to the amount covered by the related prospectus supplement, our ability to conduct new or expanded primary offerings under Form S-3 may be limited while the aggregate market value o…

• We are highly dependent on Sandesh Seth, our Chairman and Chief Executive Officer, and the loss of his services could be significantly more disruptive and costly to remediate than the loss of other members of management.

• Mr. Seth has served as our Chairman since October 2013 and as our Chief Executive Officer since June 2017, and as a director since March 2012. He has over 25 years of experience spanning investment banking, equity research, and the pharmaceutical industry, including business development, strategic p…

Text removed vs the prior filing · source: 10-Q · 2026-05-08

• Although we do not have any international operations at this time, we intend to seek market clearances in foreign markets that we believe will generate significant opportunities. However, even with the cooperation of a commercialization partner, conducting drug development in foreign countries invol…